New Strategies for Potential Diagnosis and Lifestyle in MASH
Dear Editor Metabolic dysfunction-associated steatohepatitis (MASH) is a major challenge facing global health, and new treatment options are urgently needed to break through[1,2]. Research by Lin JY et al. demonstrated that dapagliflozin has shown significant effects on patients with MASH and liver fibrosis[3]. Although the results of the study show strong persuasiveness, it may still […]